Denali Therapeutics (DNLI) Capital Leases (2024 - 2026)

Denali Therapeutics (DNLI) has 3 years of Capital Leases data on file, last reported at $5.5 million in Q1 2026.

• Quarterly Capital Leases fell 1.61% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 1.61% YoY) and the FY2025 annual result came in at $5.5 million, down 1.48% from the prior year.
• Capital Leases was little changed at $5.5 million in Q1 2026 per DNLI's latest filing, from $5.5 million in the prior quarter.
• Across five years, Capital Leases topped out at $5.6 million in Q3 2024 and bottomed at $5.5 million in Q1 2026.
• The 3-year median for Capital Leases is $5.6 million (2025), against an average of $5.6 million.
• The widest annual swing landed in 2025, when Capital Leases slipped 1.37%; it then fell 1.61% in 2026.
• Tracing DNLI's Capital Leases over 3 years: stood at $5.6 million in 2024, then retreated by 1.48% to $5.5 million in 2025, then dropped by 0.43% to $5.5 million in 2026.
• Per Business Quant, the three latest DNLI Capital Leases figures stand at $5.5 million (Q1 2026), $5.5 million (Q4 2025), and $5.6 million (Q3 2025).

Peer Comparison